May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Comparison of 24-Hour Post-Dose Efficacy of Travoprost and Latanoprost When Morning-Dosed in Open-Angle Glaucoma
Author Affiliations & Notes
  • R. Battista
    University of Western Ontario, London, Ontario, Canada
  • D. B. Yan
    University of Toronto, Toronto, Ontario, Canada
  • DBYAN Medicine Professional Corporation
    University of Western Ontario, London, Ontario, Canada
  • Footnotes
    Commercial Relationships R. Battista, None; D.B. Yan, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5567. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Battista, D. B. Yan, DBYAN Medicine Professional Corporation; Comparison of 24-Hour Post-Dose Efficacy of Travoprost and Latanoprost When Morning-Dosed in Open-Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5567.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To determine the effect of patient dosing preference on drug efficacy and to determine the IOP-lowering efficacy of AM-dosed travoprost and latanoprost is compared 24-hours post-dose.

Methods:: Open-angle glaucoma patients currently controlled on PM-dosed (2100) latanoprost (n=21) or travoprost (n=30) had baseline IOP’s measured at 0900. In a randomized, single-masked, crossover design, patients received travoprost or latanoprost at 0900 for 4 weeks, then crossed over to receive the 2nd prostaglandin for another 4 weeks. Treatment IOP was measured at 0900 prior to morning dose at both 4 and 8 week visits. Patient dosing preference (AM/PM) was surveyed on exit.

Results:: Baseline (PM-dosed) IOP was 17.9±0.5mmHg for travoprost; there was no change with AM-dosing (17.1±0.6mmHg, p=0.13). Baseline (PM-dosed) IOP was 17.7±0.5mmHg for latanoprost; there was also no change with AM-dosing (18.2±0.5mmHg, p=0.3). In the AM-dosing crossover comparison, 24-hour post-dose IOP was significantly lower (p=0.000003) on travoprost (16.9±0.4mmHg) compared to latanoprost (18.6±0.5mmHg). Latanoprost patients preferring PM-dosing significantly increased IOP (+1.5±0.6mmHg, p=0.03) with AM-dosing compared to PM-dosing; IOP was unchanged (-0.4±0.7mmHg, p=0.7) in patients that preferred AM-dosing. For travoprost, there was no significant change in IOP with AM-dosing in patients that preferred AM-dosing (-0.7±0.6mmHg, p=0.3) or PM-dosing (-0.9±1.1mmHg, p=0.5). Overall, 56% of patients preferred AM-dosing.

Conclusions:: AM-dosed travoprost is superior to AM-dosed latanoprost by 1.7 mmHg at 24-hours post-dose. Patient dosing preference affected AM-dosing efficacy for latanoprost but not for travoprost.

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.